Carbamazepine (All indications)

Caesarean

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9598
R33995		 Artama (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 Caesarean section during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 0.94 [0.62;1.43] C
excluded (control group) 		191/1,084   32/173 223 1,084
ref
S9599
R34007		 Artama (Carbamazepine) (Controls unexposed, disease free), 2013 Caesarean section during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.16 [0.99;1.36]
excluded (control group) 		191/1,084   114,791/721,948 114,982 1,084
ref
S9600
R34019		 Artama (Carbamazepine) (Controls unexposed, sick), 2013 Caesarean section during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 0.95 [0.78;1.17] 191/1,084   331/1,800 522 1,084
ref
S9751
R34815		 Borthen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010 Caesarean during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.13 [0.75;1.71] C
excluded (control group) 		81/388   44/233 125 388
ref
S9753
R34823		 Borthen (Carbamazepine) (Controls unexposed, disease free), 2010 Caesarean during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.50 [1.20;1.90]
excluded (control group) 		81/388   51,806/362,302 51,887 388
ref
S9755
R34831		 Borthen (Carbamazepine) (Controls unexposed, sick), 2010 Caesarean during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No 1.19 [0.91;1.57] C 81/388   337/1,863 418 388
ref
S9615
R34164		 Endo (Carbamazepine) (Controls unexposed, disease free), 2004 Cesarean section throughout pregnancy retrospective cohort unexposed, disease free excluded Adjustment: No 7.86 [1.93;32.11] C
excluded (control group) 		4/8   74/656 78 8
ref
S9616
R34179		 Endo (Carbamazepine) (Controls unexposed, sick), 2004 Cesarean section throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 1.29 [0.02;82.50] C 4/8   0/1 4 8
ref
Total 3 studies 1.03 [0.88;1.21] 944 1,480
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Artama (Carbamazepine) (Controls unexposed, sick), 2013Artama, 2013 1 0.95[0.78; 1.17]5221,08464%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Borthen (Carbamazepine) (Controls unexposed, sick), 2010Borthen, 2010 2 1.19[0.91; 1.57]41838836%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Endo (Carbamazepine) (Controls unexposed, sick), 2004Endo, 2004 3 1.29[0.02; 82.50]480%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 1.03[0.88; 1.21]9441,4800.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.03[0.88; 1.21]9441,4800%NAArtama (Carbamazepine) (Controls unexposed, sick), 2013 Borthen (Carbamazepine) (Controls unexposed, sick), 2010 Endo (Carbamazepine) (Controls unexposed, sick), 2004 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.03[0.88; 1.21]9441,4800%NAArtama (Carbamazepine) (Controls unexposed, sick), 2013 Borthen (Carbamazepine) (Controls unexposed, sick), 2010 Endo (Carbamazepine) (Controls unexposed, sick), 2004 3 Tags Adjustment   - No  - No 1.20[0.91; 1.57]4223960%NABorthen (Carbamazepine) (Controls unexposed, sick), 2010 Endo (Carbamazepine) (Controls unexposed, sick), 2004 2   - Yes  - Yes 0.95[0.78; 1.16]5221,084 -NAArtama (Carbamazepine) (Controls unexposed, sick), 2013 1 All studiesAll studies 1.03[0.88; 1.21]9441,4800%NAArtama (Carbamazepine) (Controls unexposed, sick), 2013 Borthen (Carbamazepine) (Controls unexposed, sick), 2010 Endo (Carbamazepine) (Controls unexposed, sick), 2004 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9615, 9751, 9753, 9598, 9599

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.48[1.00; 2.19]166,9471,48079%NAArtama (Carbamazepine) (Controls unexposed, disease free), 2013 Borthen (Carbamazepine) (Controls unexposed, disease free), 2010 Endo (Carbamazepine) (Controls unexposed, disease free), 2004 3 unexposed, sick controlsunexposed, sick controls 1.03[0.88; 1.21]9441,4800%NAArtama (Carbamazepine) (Controls unexposed, sick), 2013 Borthen (Carbamazepine) (Controls unexposed, sick), 2010 Endo (Carbamazepine) (Controls unexposed, sick), 2004 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.03[0.77; 1.38]3481,4720%NAArtama (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 Borthen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010 20.510.01.0